Closing the portal to SARS-CoV-2 cellular entry: May open newer avenues….
作者信息
Sharma Ridhima, Magoon Rohan, Kaushal Brajesh
机构信息
Department of Paediatric Anaesthesia, Superspeciality Paediatric Hospital & Postgraduate Teaching Institute, Noida 201301, India.
Department of Cardiac Anaesthesia, Atal Bihari Vajpayee Institute of Medical Sciences (ABVIMS) and Dr. Ram Manohar Lohia Hospital, Baba Kharak Singh Marg, New Delhi 110001, India.
出版信息
Med Hypotheses. 2021 Jan;146:110464. doi: 10.1016/j.mehy.2020.110464. Epub 2020 Dec 22.
Abstract
摘要
相似文献
1
Closing the portal to SARS-CoV-2 cellular entry: May open newer avenues….关闭SARS-CoV-2细胞进入的门户：可能会开辟新的途径……
Med Hypotheses. 2021 Jan;146:110464. doi: 10.1016/j.mehy.2020.110464. Epub 2020 Dec 22.
2
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.甲磺酸那法莫司他可阻断新型冠状病毒激活：新冠肺炎的新治疗选择。
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00754-20.
3
Existence of SARS-CoV-2 Entry Molecules in the Oral Cavity.口腔中存在 SARS-CoV-2 进入分子。
Int J Mol Sci. 2020 Aug 20;21(17):6000. doi: 10.3390/ijms21176000.
4
Expression Pattern of the SARS-CoV-2 Entry Genes and in the Respiratory Tract.SARS-CoV-2 进入基因在呼吸道中的表达模式。
Viruses. 2020 Oct 16;12(10):1174. doi: 10.3390/v12101174.
5
Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart.单细胞分析 SARS-CoV-2 受体 ACE2 和刺突蛋白在人心脏中对蛋白酶的预激活表达。
Cardiovasc Res. 2020 Aug 1;116(10):1733-1741. doi: 10.1093/cvr/cvaa191.
6
SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors.SARS-CoV-2 宿主嗜性：主要细胞因子的计算分析。
Virus Res. 2020 Nov;289:198154. doi: 10.1016/j.virusres.2020.198154. Epub 2020 Sep 9.
7
TMPRSS2 and ACE2 Coexpression in SARS-CoV-2 Salivary Glands Infection.TMPRSS2与ACE2在新型冠状病毒唾液腺感染中的共表达
J Dent Res. 2020 Sep;99(10):1120-1121. doi: 10.1177/0022034520933589. Epub 2020 Jun 1.
8
Expression of angiotensin-converting enzyme 2 and proteases in COVID-19 patients: A potential role of cellular FURIN in the pathogenesis of SARS-CoV-2.血管紧张素转化酶 2 和蛋白酶在 COVID-19 患者中的表达：细胞 FURIN 在 SARS-CoV-2 发病机制中的潜在作用。
Med Hypotheses. 2020 Oct;143:109893. doi: 10.1016/j.mehy.2020.109893. Epub 2020 May 30.
9
Not only ACE2-the quest for additional host cell mediators of SARS-CoV-2 infection: Neuropilin-1 (NRP1) as a novel SARS-CoV-2 host cell entry mediator implicated in COVID-19.不仅仅是ACE2——对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的其他宿主细胞介质的探索：神经纤毛蛋白-1（NRP1）作为一种与2019冠状病毒病（COVID-19）相关的新型SARS-CoV-2宿主细胞进入介质
Signal Transduct Target Ther. 2021 Jan 18;6(1):21. doi: 10.1038/s41392-020-00460-9.
10
Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.通过实验已知的抑制剂甲磺酸卡莫司他、那法莫司他和盐酸溴己新控制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）时TMPRSS2的结构见解和抑制机制：一种分子建模方法
Inform Med Unlocked. 2021;24:100597. doi: 10.1016/j.imu.2021.100597. Epub 2021 May 26.
本文引用的文献
1
Inhaled milrinone for sick COVID-19 cohort: A pathophysiology driven hypothesis!吸入米力农治疗新冠重症患者队列：基于病理生理学的假说！
Med Hypotheses. 2021 Jan;146:110441. doi: 10.1016/j.mehy.2020.110441. Epub 2020 Nov 29.
2
Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation.甲磺酸卡莫司他可能减轻新型冠状病毒肺炎脓毒症的严重程度：首次观察结果
Crit Care Explor. 2020 Nov 16;2(11):e0284. doi: 10.1097/CCE.0000000000000284. eCollection 2020 Nov.
3
Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.甲磺酸卡莫司他治疗 SARS-CoV-2 和 COVID-19 的作用机制、剂量和安全性。
Basic Clin Pharmacol Toxicol. 2021 Feb;128(2):204-212. doi: 10.1111/bcpt.13533. Epub 2020 Nov 22.
4
SARS-CoV-2 cell entry receptor ACE2 mediated endothelial dysfunction leads to vascular thrombosis in COVID-19 patients.严重急性呼吸综合征冠状病毒 2 细胞进入受体血管紧张素转换酶 2 介导的内皮功能障碍导致 COVID-19 患者血管血栓形成。
Med Hypotheses. 2020 Dec;145:110320. doi: 10.1016/j.mehy.2020.110320. Epub 2020 Sep 30.
5
Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.三例 COVID-19 肺炎老年患者需要氧疗时使用那屈肝素的治疗案例。
Int J Infect Dis. 2020 Jul;96:500-502. doi: 10.1016/j.ijid.2020.05.072. Epub 2020 May 26.
6
Potential of heparin and nafamostat combination therapy for COVID-19.肝素与那法莫司他联合治疗新冠肺炎的潜力
J Thromb Haemost. 2020 Jun;18(6):1521-1522. doi: 10.1111/jth.14858. Epub 2020 May 6.
7
Systematic approaches towards the development of host-directed antiviral therapeutics.开发宿主导向抗病毒疗法的系统方法。
Int J Mol Sci. 2011;12(6):4027-52. doi: 10.3390/ijms12064027. Epub 2011 Jun 15.
Zotero 插件